US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bicara Therapeutics

18.51

+0.73004.11%

Post-market: 17.05-1.4600-7.89%19:44 EDT

Volume:949.57K

Turnover:17.75M

Market Cap:1.01B

PE:-7.87

High:19.71

Open:18.55

Low:17.46

Close:17.78

52wk High:28.09

52wk Low:7.80

Shares:54.61M

Float Shares:24.13M

Volume Ratio:1.69

T/O Rate:3.93%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3513

EPS(LYR):-4.0460

ROE:-32.71%

ROA:-22.85%

PB:2.32

PE(LYR):-4.57

Loading ...

Overview Company News Filings

BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv

Bicara Shares Rise Premarket on FDA Breakthrough Designation

Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer

Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L Hpv-Negative R/M Hnscc

THOMSON REUTERS

Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares

Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares

Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of Common Shares

Bicara Therapeutics Files $400 Million Mixed Shelf

MT Newswires Live

BRIEF-Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400 Million - SEC Filing

Bicara Therapeutics files $400M mixed securities shelf

TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Chief Legal Officer Lara Meisner Reports Disposal of Common Shares

Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating

Bicara Therapeutics Shares Jump 16% Premarket After Peer Merus to Be Acquired by Genmab for $8 Bln

THOMSON REUTERS

Top Premarket Gainers

MT Newswires Live

Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Bicara Therapeutics Initiated at Overweight by Piper Sandler

Piper Sandler Initiates Bicara Therapeutics at Overweight

MT Newswires Live

Stock Track | Bicara Therapeutics Soars 5.54% Following Q2 2025 Earnings Release

Bicara Therapeutics Q2 EPS $(0.50) Beats $(0.54) Estimate

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BCAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":18.51,"timestamp":1760385600000,"preClose":17.78,"halted":0,"volume":949574,"hourTrading":{"tag":"盘后","latestPrice":17.05,"preClose":18.51,"latestTime":"19:44 EDT","volume":10773,"amount":198198.6507,"timestamp":1760399094758},"delay":0,"floatShares":24134001,"shares":54612477,"eps":-2.351251,"marketStatus":"Closed","change":0.73,"latestTime":"10-13 16:00:00 EDT","open":18.55,"high":19.71,"low":17.4563,"amount":17754873.51915,"amplitude":0.126755,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.351251,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1760428800000},"marketStatusCode":5,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":17.78,"preHourTrading":{"tag":"盘前","latestPrice":18.85,"preClose":17.78,"latestTime":"09:29 EDT","volume":43755,"amount":902131.66398,"timestamp":1760362199929},"postHourTrading":{"tag":"盘后","latestPrice":17.05,"preClose":18.51,"latestTime":"19:44 EDT","volume":10773,"amount":198198.6507,"timestamp":1760399094758},"volumeRatio":1.686882,"impliedVol":0.8156,"impliedVolPercentile":0.7615},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":24134001,"roa":"-22.85%","roe":"-32.71%","lyrEps":-4.045991,"volumeRatio":1.686882,"shares":54612477,"dividePrice":0,"high":19.71,"amplitude":0.126755,"preClose":17.78,"low":17.4563,"week52Low":7.8,"pbRate":"2.32","week52High":28.09,"institutionHeld":0,"latestPrice":18.51,"eps":-2.351251,"divideRate":0,"volume":949574,"delay":0,"ttmEps":-2.351251,"open":18.55,"prevYearClose":17.42,"prevWeekClose":17.78,"prevMonthClose":15.79,"prevQuarterClose":15.79,"fiveDayClose":18.03,"twentyDayClose":11.38,"sixtyDayClose":10.93},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5},{"market":"US","date":"2025-05-13","symbol":"BCAX","fiscalQuarterEnding":"2025/03","expectedEps":-0.4,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-03-27","symbol":"BCAX","fiscalQuarterEnding":"2024/12","expectedEps":-0.31,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1743048000000,"reportTimeType":"pre","actualEps":-0.39},{"market":"US","date":"2024-11-12","symbol":"BCAX","fiscalQuarterEnding":"2024/09","expectedEps":-0.46,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.6}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1757649600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2025-10-10","current":-7.872405,"percent":0.576208,"low":-22.704836,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"high":-5.144536,"avg":-11.594175,"sd":5.10282,"marketCap":997223830},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830}],"updateTime":1760412697247},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2575281804","title":"BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv","url":"https://stock-news.laohu8.com/highlight/detail?id=2575281804","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575281804?lang=en_us&edition=fundamental","pubTime":"2025-10-14 01:46","pubTimestamp":1760377569,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, VertivEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nL6N3VU0HC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNA","TVRD","MACW.SI","NPO","LU0496367417.USD","TGT","KDP","SCCO","NDRA","BK4567","XOM","FAST","BK4500","BK4566","AGX","CVX","NEM","PGEN","DVN","LNT","SRRK","BK4155","STUB","STX","LU2054465674.USD","ALK","LU0878866978.SGD","COP","JEF","ABEO","BCAX","CERO","LU1571399168.USD","MKSI","ARDX","SG9999014542.SGD","VRT"],"gpt_icon":1},{"id":"2575405295","title":"Bicara Shares Rise Premarket on FDA Breakthrough Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405295","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405295?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:04","pubTimestamp":1760357040,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics rose sharply in premarket trading Monday after the clinical-stage biopharmaceutical company won U.S. Food and Drug Administration breakthrough-therapy designation for its lead program, ficerafusp alfa, in certain head and neck cancers.Bicara on Monday said the designation covers ficerafusp alfa in combination with Merck's blockbuster cancer drug Keytruda for first-line treatment of patients with metastatic or with unresectable, recurrent head and neck squamous cell carcinoma that is human papillomavirus-negative.The Boston company said HPV-negative head-and-neck squamous cell carcinoma has particularly poor outcomes and limited therapeutic options.The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug might offer substantial improvement over available therapies.Bicara shares, which closed Friday at $17.78, were recently up 40% to $24.98 in pre","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014575.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","LU2023250843.SGD","SG9999014559.SGD","IE00BJT1NW94.SGD","BK4588","SG9999002232.USD","LU0070302665.USD","LU0238689110.USD","LU0106261372.USD","SG9999001176.SGD","IE00BLSP4452.SGD","SG9999014567.USD","MRK","LU1066051225.USD","LU0006306889.USD","BCAX","IE00B2B36J28.USD","LU1941712264.USD","LU0965509101.SGD","IE00B4R5TH58.HKD","LU1069347547.HKD","LU0234572021.USD","LU0965508806.USD","LU1917777945.USD","LU0208291251.USD","IE0002141913.USD","LU1023059063.AUD","SG9999015341.SGD","LU1974910355.USD","LU0203345920.USD","LU0320765489.SGD","LU1061106388.HKD","LU2324357040.USD","LU0265550359.USD","LU1116320737.USD","LU1699723380.USD","LU1093756325.SGD","LU1093756168.USD","LU2361045086.USD","LU1934455194.USD","LU0265550946.USD","LU0211331839.USD","LU1941712348.USD","LU1989772840.SGD","LU0266013472.USD","LU1430594728.SGD","IE0009355771.USD","BK4534"],"gpt_icon":0},{"id":"2575354403","title":"Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2575354403","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575354403?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:31","pubTimestamp":1760355073,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Receives FDA Breakthrough Therapy Designation for Ficerafusp Alfa in First-Line HPV-Negative Head and Neck Cancer. Bicara Therapeutics Inc. announced that the U.S. Food and Drug Administration  has granted Breakthrough Therapy Designation  to ficerafusp alfa in combination with pembrolizumab for the first-line treatment of patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma  whose tumors express PD-L1 , excluding HPV-positive oropharyngeal squamous cell carcinoma. The designation is based on promising results from multiple Phase 1/1b cohorts, which demonstrated significant clinical benefit and a favorable safety profile. This regulatory milestone is intended to expedite the development and review of ficerafusp alfa, highlighting its potential to address an urgent unmet need in HPV-negative HNSCC. The grant was announced solely by Bicara Therapeutics Inc.Disclaimer: This news brief was created by Public Technologies  using genera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL6ZTwR1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","LU2095319765.USD","NDAQ","IE00B3QW5Z07.USD","BK4585","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4588","BCAX","BK4139"],"gpt_icon":0},{"id":"2575403887","title":"Bicara Therapeutics Announces Ficerafusp Alfa Granted Breakthrough Therapy Designation by U.S. FDA for 1L Hpv-Negative R/M Hnscc","url":"https://stock-news.laohu8.com/highlight/detail?id=2575403887","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575403887?lang=en_us&edition=fundamental","pubTime":"2025-10-13 19:30","pubTimestamp":1760355058,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nTUA1QFSQ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2574488627","title":"Bicara Therapeutics Chief Medical Officer David Raben Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574488627","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574488627?lang=en_us&edition=fundamental","pubTime":"2025-10-11 05:23","pubTimestamp":1760131430,"startTime":"0","endTime":"0","summary":"David Raben, Chief Medical Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL9lhf9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2574620488","title":"Bicara Therapeutics CFO Ivan Hyep Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574620488","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574620488?lang=en_us&edition=fundamental","pubTime":"2025-10-11 05:23","pubTimestamp":1760131414,"startTime":"0","endTime":"0","summary":"Ivan Hyep, Chief Financial Officer of Bicara Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 10, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251010:nNDL28hsmK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2574908936","title":"Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2574908936","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574908936?lang=en_us&edition=fundamental","pubTime":"2025-10-09 05:34","pubTimestamp":1759959248,"startTime":"0","endTime":"0","summary":"Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc., reported a disposal of common shares of Bicara Therapeutics Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 08, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL110XCF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2572351596","title":"Bicara Therapeutics Files $400 Million Mixed Shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2572351596","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572351596?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:53","pubTimestamp":1759524790,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics  on Friday filed a registration statement with the US Securities and Exchange Commission to issue up to $400 million of securities.The filing also includes a sales-agreement prospectus to sell up to $150 million of common stock under an at-the-market arrangement with TD Securities, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2572635800","title":"BRIEF-Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2572635800","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572635800?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:37","pubTimestamp":1759523864,"startTime":"0","endTime":"0","summary":"BRIEF-Bicara Therapeutics Files For Mixed Shelf Offering Of Up To $400 Million - SEC FilingOct 3  - Bicara Therapeutics Inc BCAX.O:BICARA THERAPEUTICS INC : FILES FOR MIXED SHELF OFFERING OF UP TO $400 MILLION - SEC FILINGSource text: [ID:n0001193125-25-230307]Further company coverage: BCAX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251003:nFWN3VK0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2572635528","title":"Bicara Therapeutics files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2572635528","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572635528?lang=en_us&edition=fundamental","pubTime":"2025-10-04 04:35","pubTimestamp":1759523706,"startTime":"0","endTime":"0","summary":"16:34 EDT Bicara Therapeutics (BCAX) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-files-400m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-files-400m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2572514993","title":"TD Cowen Keeps Their Buy Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2572514993","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572514993?lang=en_us&edition=fundamental","pubTime":"2025-10-02 19:55","pubTimestamp":1759406115,"startTime":"0","endTime":"0","summary":"In a report released on September 30, Tyler Van Buren from TD Cowen maintained a Buy rating on Bicara Therapeutics Inc.. The company’s shares close...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-bicara-therapeutics-inc-bcax-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TD","BCAX","COWN"],"gpt_icon":0},{"id":"2572550263","title":"Bicara Therapeutics Chief Legal Officer Lara Meisner Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2572550263","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572550263?lang=en_us&edition=fundamental","pubTime":"2025-10-02 04:58","pubTimestamp":1759352315,"startTime":"0","endTime":"0","summary":"Lara Meisner, Chief Legal Officer of Bicara Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL1ftQ93:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"gpt_icon":0},{"id":"2571457063","title":"Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2571457063","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571457063?lang=en_us&edition=fundamental","pubTime":"2025-09-30 18:16","pubTimestamp":1759227360,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer has maintained their bullish stance on BCAX stock, giving a Buy rating yesterday. Judah Frommer has given his ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-market-opportunity-for-bicara-therapeutics-in-hpv-negative-head-neck-cancer-warrants-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-market-opportunity-for-bicara-therapeutics-in-hpv-negative-head-neck-cancer-warrants-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"gpt_icon":0},{"id":"2571335598","title":"Bicara Therapeutics Shares Jump 16% Premarket After Peer Merus to Be Acquired by Genmab for $8 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2571335598","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571335598?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:30","pubTimestamp":1759149034,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"484c19b5e334de9a1873457964a50ace","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nL3N3VG0SG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"gpt_icon":0},{"id":"2571338359","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2571338359","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571338359?lang=en_us&edition=fundamental","pubTime":"2025-09-29 19:53","pubTimestamp":1759146790,"startTime":"0","endTime":"0","summary":"JFB Construction  shares were almost 94% higher pre-bell Monday after the company said late Friday that it has secured a private placement deal with American Ventures for up to $44 million in equity financing.Dogwood Therapeutics  stock was up 60% after the company said it has secured an exclusive worldwide, royalty license to develop and commercialize Serpin Pharma's SP16 as a treatment for cancer-related pain.Steakholder Foods  shares were 46% higher following a muted session.Merus  stock was up 38% on a pending $8 billion takeover by Genmab .Bicara Therapeutics  shares were 20% higher, adding to Friday's gains.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","DWTX","LU0109394709.USD","GMAB","BCAX","BK4139","BK4212","BK4129","MRUS","STKH","JFB","LU0320765992.SGD"],"gpt_icon":0},{"id":"2561476529","title":"Bicara Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2561476529","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561476529?lang=en_us&edition=fundamental","pubTime":"2025-08-22 19:13","pubTimestamp":1755861180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 22, 2025 07:13 ET (11:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2560719612","title":"Bicara Therapeutics Initiated at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2560719612","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560719612?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:58","pubTimestamp":1755604680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BCAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2025 07:58 ET (11:58 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0},{"id":"2560193661","title":"Piper Sandler Initiates Bicara Therapeutics at Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2560193661","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560193661?lang=en_us&edition=fundamental","pubTime":"2025-08-19 19:06","pubTimestamp":1755601582,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (BCAX) has an average rating of buy and mean price target of $33.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCAX"],"gpt_icon":0},{"id":"1192233806","title":"Stock Track | Bicara Therapeutics Soars 5.54% Following Q2 2025 Earnings Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1192233806","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192233806?lang=en_us&edition=fundamental","pubTime":"2025-08-13 22:02","pubTimestamp":1755093745,"startTime":"0","endTime":"0","summary":"Shares of Bicara Therapeutics (BCAX) are soaring in Wednesday's trading session, with the stock climbing 5.54% as investors react to the company's recently released second-quarter earnings report for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BCAX"],"gpt_icon":0},{"id":"2558641605","title":"Bicara Therapeutics Q2 EPS $(0.50) Beats $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2558641605","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558641605?lang=en_us&edition=fundamental","pubTime":"2025-08-12 19:33","pubTimestamp":1754998429,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.54) by 7.41 percent. This is a 97.37 percent increase over losses of $(19.01) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47055087/bicara-therapeutics-q2-eps-0-50-beats-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":42,"code":"91000000","status":"200"}]}}